logo-loader
viewGENFIT

Genfit SA expecting Phase 3 results of its NASH therapy by 1Q

Genfit SA (NASDAQ:GNFT) CEO Pascal Prigent sat down with Proactive’s Christine Corrado at BIO CEO in New York.

The biopharmaceutical company, based in France, is developing therapeutic and diagnostic solutions for metabolic and liver related diseases.

Quick facts: GENFIT

Price: 14.6 USD

NASDAQ:GNFT
Market: NASDAQ
Market Cap: $566.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Power Metal Resources 'pushing ahead with key projects' and in strong...

Power Metal Resources Plc's (LON:POW) Paul Johnson tells Proactive London's Andrew Scott they're in an advantageous financial position to deal with the current uncertainty around the coronavirus outbreak. He says they're conducting business diligently, safeguarding existing business...

18 hours, 35 minutes ago

2 min read